Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 2/20 | 0.44 |
| ▸ | TGFBR1 | P36897 | 7/20 | 0.43 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.42 |
| ▸ | ACP1 | P24666 | 3/20 | 0.39 |
| ▸ | ELANE | P08246 | 1/20 | 0.39 |
| ▸ | KMO | O15229 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31032681 | 0.84 | TGFBR1 (0.45) | TGFBR1ASIC3KMOSCN9A | |
| SCHEMBL2596864 | 0.84 | TGFBR1 (0.45) | TGFBR1ASIC3KMOSCN9A | |
| SCHEMBL12090613 | 0.82 | ACP1 (0.48) | GRM2TGFBR1ACP1SCN9A | |
| SCHEMBL1818697 | 0.81 | GRM2 (0.42) | GRM2TGFBR1ACP1KMOACHE | |
| Urea SCHEMBL1817197 | 0.77 | GRM2 (0.48) | GRM2TGFBR1KMOACHEMAPK1 | |
| SCHEMBL12090592 | 0.75 | ACP1 (0.53) | TGFBR1ACP1SCN9A | |
| SCHEMBL2328148 | 0.75 | GRM2 (0.45) | GRM2TGFBR1ACP1ELANEMAPK1 | |
| SCHEMBL12657827 | 0.75 | GRM2 (0.44) | GRM2TGFBR1ACP1ELANEMAPK1 | |
| SCHEMBL1817198 | 0.75 | GRM2 (0.44) | GRM2ACP1ELANEMAPK1 | |
| SCHEMBL12090569 | 0.75 | TGFBR1 (0.57) | TGFBR1ACP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8987301-B2 | Heteroarylaminoquinolines as TGF-beta receptor kinase inhibitors | MERCK PATENT GMBH (DE) | 2015-03-24 | — | — | US | disclosed |
| EP-2496234-A1 | HETEROARYLAMINOQUINOLINES AS TGF-BETA RECEPTOR KINASE INHIBITORS | Merck Patent GmbH (DE) | 2012-09-12 | — | — | EP | disclosed |
| US-20120225875-A1 | HETEROARYLAMINOQUINOLINES AS TGF-BETA RECEPTOR KINASE INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-09-06 | — | — | US | disclosed |
| WO-2011054433-A1 | HETEROARYLAMINOQUINOLINES AS TGF-BETA RECEPTOR KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2011-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225875-A1 | HETEROARYLAMINOQUINOLINES AS TGF-BETA RECEPTOR KINASE INHIBITORS | TGFBR1, TGFBR2, TGFB1 | GRM2 2058/4885TGFBR1 1/4885ASIC3 4378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.